AbCellera Biologics Inc. (ABCL) News

AbCellera Biologics Inc. (ABCL): $10.40

-0.36 (-3.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABCL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter ABCL News Items

ABCL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ABCL News Highlights

  • ABCL's 30 day story count now stands at 13.
  • Over the past 25 days, the trend for ABCL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ABCL are EYE, PAY and PLRX.

Latest ABCL News From Around the Web

Below are the latest news stories about ABCELLERA BIOLOGICS INC that investors may wish to consider to help them evaluate ABCL as an investment opportunity.

AbCellera to Report Full Year 2022 Financial Results on February 21, 2023

VANCOUVER, British Columbia, January 24, 2023--AbCellera to Report Full Year 2022 Financial Results on February 21, 2023

Yahoo | January 24, 2023

Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock?

Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.

Yahoo | January 24, 2023

AbCellera Biologics Clears Key Benchmark, Hitting 80-Plus RS Rating

A Relative Strength Rating upgrade for AbCellera Biologics shows improving technical performance.

Investor''s Business Daily | January 23, 2023

AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent

VANCOUVER, British Columbia, January 20, 2023--AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent

Yahoo | January 20, 2023

Does AbCellera Biologics (NASDAQ:ABCL) Deserve A Spot On Your Watchlist?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Yahoo | January 19, 2023

AbCellera Biologics Inc. (NASDAQ:ABCL) stock crossing the finish line today

In the current trading session, AbCellera Biologics Inc.’s (ABCL) stock is trading at the price of $10.73, a gain of 1.76% over last night’s close. So, the stock is trading at a price that is -28.36% less than its 52-week high of $14.97 and 97.88% better than its 52-week low of $5.42. Based on the […]

US Post News | January 18, 2023

Strength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength?

Pliant Therapeutics, Inc. (PLRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | January 12, 2023

AbCellera (ABCL) Stock: My Updated Current Valuation Estimate

In this article, I will provide my valuation model for AbCellera, building on an article I wrote over a year ago. See why I''m fervently bullish on ABCL stock.

Seeking Alpha | January 5, 2023

AbCellera Biologics Inc.'s (NASDAQ:ABCL) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

It is hard to get excited after looking at AbCellera Biologics' (NASDAQ:ABCL) recent performance, when its stock has...

Yahoo | January 5, 2023

AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023

VANCOUVER, British Columbia, January 04, 2023--AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023

Yahoo | January 4, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5555 seconds.